touchREVIEWS in Ophthalmology – Volume 19, Issue 1

We are delighted to share the latest issue of touchREVIEWS in Ophthalmology, showcasing a diverse range of articles that highlight the innovation, interdisciplinary collaboration and continued advances driving progress in eye care today. We begin this issue with an important and under-explored topic, as Fatma et al. present an investigative review examining the potential association […]

Thermoreceptors on the ocular surface play a critical role in the development of dry eye disease (DED). An experimental eye drop called AR-15512, which activates cooling receptors, has been found to provide fast and continuous relief from dry eye symptoms, with minimal side effects. Due to its cold-sensing stimulation, this medication may also help patients […]

Breast carcinoma is the most common cancer in females. An estimated 2.3 million new cases of breast carcinoma are diagnosed annually worldwide.1 These patients have potential risks of ocular complications not only from the secondaries in the eye but also due to the side effects of medications such as corticosteroids and cytotoxic drugs used to treat […]

On 28 May 2024, enrolment in phase III clinical trials for sozinibercept in neovascular age-related macular degeneration (nAMD) was completed.1 These trials include two large multicentre, double-masked, randomized controlled trials (RCTs): COAST (OPT-302 with aflibercept in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757636) and ShORe (OPT-302 with ranibizumab in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757610).2,3 These trials represent one of the largest phase […]

The uvea is a vascular stratum that includes the iris, ciliary body and choroid. Uveitis is defined as inflammation of a part of the uvea or its entirety, but it is also used to describe inflammatory processes of any part of the eye, such as the vitreous or peripheral retina. The clinical taxonomy of uveitis […]

Since its inception in November 2022, ChatGPT-3.5 has gained increasing popularity.1,2 ChatGPT is an artificial intelligence (AI) language application that performs online tasks and mimics human conversations using a question-and-answer format.3 The interface has found widespread use in several industries, with applications ranging from programming, business, education and healthcare.4 To contextualize this new technology, it is […]